1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Developmental and Epileptic Encephalopathy 1
Conditions
Developmental and Epileptic Encephalopathy 1
Trial Timeline
Jul 9, 2025 → Jul 1, 2027
NCT ID
NCT07010471About 1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo
1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo is a phase 3 stage product being developed by Praxis Precision Medicines for Developmental and Epileptic Encephalopathy 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07010471. Target conditions include Developmental and Epileptic Encephalopathy 1.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07010471 | Phase 3 | Recruiting |
Competing Products
4 competing products in Developmental and Epileptic Encephalopathy 1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aripiprazole oral product + Placebo oral capsule | Bristol Myers Squibb | Phase 3 | 76 |
| NBI-921352 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-921352 | Neurocrine Biosciences | Phase 2 | 49 |
| Sertraline | Brain Biotech | Phase 2 | 44 |